Compare IAC & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IAC | SUPN |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | 2020 | 2010 |
| Metric | IAC | SUPN |
|---|---|---|
| Price | $37.79 | $53.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | $45.75 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 1.1M | 748.1K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,365,235,000.00 | $392,755,000.00 |
| Revenue This Year | N/A | $23.19 |
| Revenue Next Year | $0.48 | $17.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.56 | $29.16 |
| 52 Week High | $50.49 | $59.68 |
| Indicator | IAC | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 53.03 | 55.71 |
| Support Level | $35.08 | $47.95 |
| Resistance Level | $38.07 | $58.67 |
| Average True Range (ATR) | 1.38 | 2.33 |
| MACD | 0.32 | 0.13 |
| Stochastic Oscillator | 80.21 | 41.87 |
IAC Inc is comprised of businesses including Angi Inc, Dotdash Meredith and Care.com, among many others ranging from early stage to established businesses. Its Dotdash Meredith segment consists of its Digital and Print businesses. Angi segment offers repairing and remodeling homes to cleaning and landscaping services. Care.com segment is a online destination for families to connect with caregivers for their children, aging parents, pets and homes and for caregivers to connect with families seeking care services. Search segment consists of a collection of websites providing general search services and information, and a Desktop business, which includes business-to-business partnership operations.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.